• YAKHAK HOEJI
• /
• v.52 no.2
• /
• pp.147-150
• /
• 2008

Previously, we reported on the antibiotic resistance patterns of 50 strains of Staphylococcus aureus which were isolated from a hospital in Busan, Korea from July 2005 to December 2006. We have isolated small plasmids and classified plasmid types by agarose gel electrophoresis. We have selected 5 plasmids and determined complete nucleotide sequences of those plasmids. The aim of this paper is to report on the characteristics of cadmium, erythromycin, lincomycin resistance plasmids and a cryptic plasmid based on the sequence analysis obtained by using the BLAST program.

• Advances in pediatric surgery
• /
• v.18 no.1
• /
• pp.30-34
• /
• 2012

Delayed gastric emptying (DGE) commonly occurs after Nissen fundoplication in patients with gastroesophageal reflux disease. Since the understanding of its pathogenesis is insufficient, an effective method of management has not yet been suggested. The authors report a case of a 16-year-old girl with DGE after laparoscopic Nissen fundoplication and treated with intravenous injection of low dose erythromycin.

• Biomedical Science Letters
• /
• v.30 no.1
• /
• pp.32-35
• /
• 2024

In vitro antimicrobial activities of hot water extracts of Chamaecyparis obtuse, for methicillin-resistant Staphylococcus aureus (MRSA) was compared to commonly used conventional antimicrobial agents. All MRSA was susceptible to linezolid or vancomycin, but also to erythromycin. MIC range and MIC₉₀ to erythromycin, clindamycin, levofloxacin, tetracycline for MRSA were each 4 ㎍/mL, 2 ~ >128 ㎍/mL, ≤0.06 ~ >128 ㎍/mL, 0.25 ~ >128 ㎍/mL, 0.25~64 ㎍/mL and 4 ㎍/mL, .128 ㎍/mL, >128 ㎍/mL, >128 ㎍/mL, 64 ㎍/mL. The hot water extracts of leaf of C. obtuse had the lowest MIC range, MIC₅₀, and MIC₉₀ (0.125 µL/mL) for the MRSA tested, and it was possible more potent than various conventional antimicrobial agents. Screen antibacterial drug candidate with high antibacterial activity such as derivatives of C. obtuse leaf extract such as terpinen-4-ol or using combined therapy with commercialized antibacterial agents will likely be helpful in treating refractory MRSA infections.

• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.236.1-236.1
• /
• 2001

• Proceedings of the PSK Conference
• /
• 2000.04a
• /
• pp.167.1-167.1
• /
• 2000

• Journal of the Korean Society of Food Science and Nutrition
• /
• v.16 no.4
• /
• pp.364-370
• /
• 1987

A lysozyme is isolated and purified partially form the egg white of Korean native Ogol fowl(Natural monument No. 265) by the method of direct crystallization. The bacteriolytic activities of 1% lysozyme against Staphylococus aureus 57, Bacillus subtilis ATCC 6633, and Escherichia coli NIHJ-JC2 was investigated with or without some other antibacterial materials in the nutrient broth culture. According to the results, 1% lysozyme showed the appreciable bacterolytic activities of about 12-16% to the almost of bacteria cultured. The synergistic effect with the lysozyme and some antibacterial materials on the growth inhibition of the bacteria cultured exhibited higher in order of the 0.001% magnolol -22%, the 0.001% honokiol -14% against S. aureus and of the 0.0005% erythromcin -29%, the honokiol -22%, the magnolol -l7%, the 0.005% phospholipase -6% against E. coli. And that synergistic effect against B. subtilis showed a fairly high level of about 52% with the erythromycin but not any effect with others.

• KSBB Journal
• /
• v.14 no.6
• /
• pp.682-687
• /
• 1999

Virginiae butanolide C(VB-C) is one of the butyrolactone autoregulators, which triggers the production of virginiamycin in Streptomyces virginiae. In order to investigate the function of VB-C as inducer in other strains, Streptomyces erythraeus was used as a test strain(parent). VB-C binding receptor gene was introduced into S. erythraeus(transformant) and the production of VBs and specific VB-C binding protein were analysed in parent and transformant. When 300ng/ml of the synthetic VB-C was added at 0, 20, 44 h cultivation of the parent and at 44 h cultivation of the transformant, the initial production times a antibiotics were shortened by more than 8 and 6 h, respectively. The transformant showed strong antibiotic activity against B. subtilis. These results suggest that the VB-C might have an ability to induce the production of secondary metabolites in S. erythraeus.

• Journal of Plant Biotechnology
• /
• v.30 no.2
• /
• pp.189-194
• /
• 2003

Contamination of bacterial infection is one of serious problems in in vitro culture system of root crops. From the contaminated tubes over 140 of petiole cultures of Pinellia ternata, a medicinal plant, 4 genera 8species 48 strains of bacteria, including Aeromonas and Pseudomonas, were isolated and identified and another 8 strains were not fully identified. Most of them were motile Gram positive bacteria as in common in early stage of in vitro cultures. Six strains of bacteria, 5 of Gram negative, including Enterobacter, and 1 of Gram positive, were identified from the embryonic axes cultures of tea plant. From the susceptibility test to pre-screened 5 antibiotics, all of the bacteria except for 2 species of Pseudomonas were susceptible to cefotaxime 60∼100mg/L. While 60mg/L erythromycin only was effective to Pseudomonas. Combination of erythromycin 20mg/L and cefotaxime 60mg/L totally suppressed the growth of all bacterial strains tested. Susceptibility test of bacteria from tea embryonic axes cultures showed similar results. Combination of erythromycin 35mg/L and cefotaxime 60mg/L was effective to 15 bacterial strains and partially effective to 1 unidentified.

• Archives of Pharmacal Research
• /
• v.29 no.12
• /
• pp.1154-1157
• /
• 2006

The ermK gene from Bacillus lichenformis encodes an inducible rRNA methylase that confers resistance to the macrolide-lincosamide-streptogramin B antibiotics. The ermK mRNA leader sequence has a total length of 357 nucleotides and encodes a 14-amino acid leader peptide together with its ribosome binding site. The secondary structure of ermK leader mRNA and a leader peptide sequence have been reported as the elements that control expression. In this study, the contribution of specific leader peptide amino acid residues to induction of ermK was studied using the PCR-based megaprimer mutation method. ermK methylases with altered leader peptide codons were translationally fused to E. coli ${\beta}-galactosidase$ reporter gene. The deletion of the codons for Thr-2 through Ser-4 reduced inducibility by erythromycin, whereas that for Thr-2 and His-3 was not. The replacement of the individual codons for Ser-4, Met-5 and Arg-6 with termination codon led to loss of inducibility, but stop mutation of codon Phe-9 restored inducibility by erythromycin. Collectively, these findings suggest that the codons for residue 4, 5 and 6 comprise the critical region for induction. The stop mutation at Leu-7 expressed constitutively ermK gene. Thus, ribosome stalling at codon 7 appears to be important for ermK induction.

• Journal of fish pathology
• /
• v.13 no.1
• /
• pp.45-51
• /
• 2000

Bacterial diseases with mixed infection have recently occurred at land-based flounder farms in Korea. Thus, single antibacterial is not effective for therapy of mixed bacterial diseases of fish because of their different causative bacteria. The purpose of the present study was to obtain basic data for positive usefulness of a combination of antibacterials used for synergism to mixed bacterial diseases of fish. Snergistic interaction in combination of antibacterials was determined by in vitro antimicrobial activity against selected fish-pathogenic bacteria, Vibrio anguillarum, Edwardsiella tarda, Streptococcus sp., Staphylococcus epidermidis, on the basis of Checkerboard assay using fractional inhibitory concentration (FIC) indices. Synergistic interactions were observed in combinations of (oxytetracycline HCL+lincomycin), (tetracycline HCL+florfenicol), (oxytetracycline HCL+florfenicol) against V. anguillarum, (sodium nifurstyrenate+florfenicol), (tetracycline HCL+florfenicol), (sodium nifurstyrenate+oxolinic acid), (oxytetracycline HCL+florfenicol) against E. tarda, (ciprofloxacine+oleandomycin), (oxytetracycline HCL+oleandomycin), (tetracycline HCL+oleandomycin), (oxytetracycline HCL+lincomycin), (oxytetracycline HCL+spiramycin), (oxytetracycline HCL+erythromycin), (doxycycline HCL+oleandomycin), (tetracycline HCL+spiramycin) against Streptococcus sp., and (ciprofloxacine+erythromycin), (florfenicol+erythromycin), (doxycycline HCL+oleandomycin), (ciprofloxacine+oleandomycin) against S. epidermidis.